The NHS DigiTrials service is helping clinical trials to use NHS Digital data much more efficiently, reducing the time, effort and cost of developing new drugs, treatments and services. During the past year, we have supported the NHS-Galleri trial, the world’s largest trial of a new blood test that can detect more than 50 types of cancer before symptoms appear. It is run by the Cancer Research UK and King’s College London Cancer Prevention Trials Unit, in partnership with the NHS and healthcare company GRAIL, and is using NHS DigiTrials to support recruitment, recalls for follow up and the tracking of patient outcomes using NHS Digital data, including data from NDRS. By using routinely collected, national NHS data sets to identify the right people, the burden on frontline staff is reduced. The NHS DigiTrials service helped to recruit a representative population into the trial (for example, by giving access to good distribution across all socioeconomic groups) to ensure the test works for everyone. 140,000 people from across the UK were recruited for the trial, making it the fastest ever recruiting large-scale randomised trial.
In April 2021, the Pelvic Floor Registry began collecting device and outcome-based data from all health care organisations undertaking pelvic floor procedures. This supported the government’s response to the report of the Independent Medicines and Medical Devices Safety Review, ‘First Do No Harm’. In parallel, the Surgical Devices and Implants Information System began to collect core device data from all health care organisations across all specialties in England to address requirements raised by the report. An Information Standards Notice was published in February 2022 specifying the surgical device and implants data that must be routinely captured in theatre systems.
The Medicines Information System project launched a Medicines in Pregnancy dashboard building on the analytics and reporting published in 2020-21 around the use of valproate and other anti-epileptics prescribed during pregnancy. The interactive dashboard provides better insight to support regulatory and clinical decisions.
In 2021-22, we continued to build our open data offering. We provided a secure, scalable mechanism for giving access to aggregated data for a variety of public and private uses through our visualisation and dashboard capabilities. Our public dashboard hub has served millions of users and our private dashboards have supported hundreds of health and policy professionals. In summer 2021, we created a secure environment to provide a patient-level GP COVID-19 vaccine dashboard to help GP practices and primary care networks increase vaccination uptake across their local communities. Users accessing the dashboard cover 80% of GP practices. In autumn 2021, we launched our GP Appointments Data dashboard, providing information about scheduled activity and GP appointments down to the practice level. This highlights data quality issues and gives local providers vital management information about their own activity.